Myasthenia gravis

New England Journal of Medicine

Volumn 330, Issue 25, 1994, Pages 1797-1810

  Drachman, Daniel B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MYASTHENIA GRAVIS; REVIEW; ANIMAL MODEL; ANTIBODY RESPONSE; AUTOIMMUNITY; CLINICAL FEATURE; DIAGNOSIS; DRUG THERAPY; ETIOLOGY; FATIGUE; FEVER; HEADACHE; HYPERTENSION; IMMUNOPATHOGENESIS; MOUSE; MUSCLE WEAKNESS; MYALGIA; NEPHROTOXICITY; NEUROMUSCULAR JUNCTION DISORDER; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; SURGERY; THERAPY; THYMECTOMY;

DIAGNOSIS, DIFFERENTIAL; HUMAN; IMMUNOTHERAPY; MYASTHENIA GRAVIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AZATHIOPRINE; CD4 ANTIGEN; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EDROPHONIUM; EDROPHONIUM CHLORIDE; HLA B8 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PREDNISONE; PYRIDOSTIGMINE;

EID: 0028779203     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199406233302507     Document Type: Review

References (164)

1. Fambrough DM, Drachman DB, Satyamurti S Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973; 182: 293-295
2. Patrick J, Lindstrom J Autoimmune response to acetylcholine receptor. Science 1973; 180: 871-872
3. Willis T. De anima brutorum. Oxford, England: Theatro Sheldoniano, 1672:404-6.
4. Kurtzke JF, Kurland LT. Chapter 66: the epidemiology of neurologic disease. In: Joynt RJ, ed. Clinical neurology. Rev. ed. Vol. 4. Philadelphia: J.B. Lippincott, 1992:80-8.
5. Grob D, Arsura EL, Brunner NG, Namba T The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505: 472-499
6. Osserman KE. Myasthenia gravis. New York: Grune & Stratton, 1958:80.
7. Chang CE, Lee CY Isolation of neurotoxins from the venom of Bungarus multicinctus and their modes of neuromuscular blocking action. Arch Pharmacodyn Ther 1962; 144: 241-257
8. Pestronk A, Drachman DB, Self SG Measurement of junctional acetylcholine receptors in myasthenia gravis: clinical correlates. Muscle Nerve 1985; 8: 245-251
9. Engel AG, Tsujihata M, Lindstrom JM, Lennon VA The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis: a quantitative ultrastructural study. Ann N Y Acad Sci 1976; 274: 60-79
10. Elmqvist D, Hofmann WW, Kugelberg J, Quastel DMJ An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J Physiol (Lond) 1964; 174: 417-434
11. Stalberg E, Trontelj JV, Schwartz MS Single-muscle-fiber recording of the jitter phenomenon in patients with myasthenia gravis and in members of their families. Ann N Y Acad Sci 1976; 274: 189-202
12. Barrett EF, Magleby KL. Physiology of cholinergic transmission. In: Goldberg AM, Hanin I, eds. Biology of cholinergic function. New York: Raven Press, 1976:29-100.
13. Kistler J, Stroud RM, Klymkowsky MW, Lalancette RA, Fairclough RH Structure and function of an acetylcholine receptor. Biophys J 1982; 37: 371-383
14. Changeux J-P. Functional architecture and dynamics of the nicotinic acetylcholine receptor: an allosteric ligand-gated ion channel. In: Changeux J-P, Llinas RR, Purves D, Bloom FE. Fidia Research Foundation neuroscience award lectures. Vol. 4: 1988-1989. New York: Raven Press, 1990:21-168.
15. Kachalsky SG, Aladjem M, Barchan D, Fuchs S The ligand binding domain of the nicotinic acetylcholine receptor: immunological analysis. FEBS Lett 1993; 318: 264-268
16. Fambrough DM Control of acetylcholine receptors in skeletal muscle. Physiol Rev 1979; 59: 165-227
17. Witzemann V, Barg B, Nishikawa Y, Sakmann B, Numa S Differential regulation of muscle acetylcholine receptor γ- and ε-subunit mRNAs. FEBS Lett 1987; 223: 104-112
18. Ramsay DA, Drachman DB, Drachman RJ, Stanley EF Stabilization of acetylcholine receptors at the neuromuscular synapse: the role of the nerve. Brain Res 1992; 581: 198-207
19. Stanley EF, Drachman DB Denervation accelerates the degradation of junctional acetylcholine receptors. Exp Neurol 1981; 73: 390-396
20. Salpeter MM. Development and neural control of the neuromuscular junction and of the junctional acetylcholine receptor. In: Salpeter MM, ed. The vertebrate neuromuscular junction. Vol. 23 of Neurology and neurobiology. New York: Alan R. Liss, 1987:55-115.
21. Drachman DB, Stanley EF, Pestronk A, Griffin JW, Price DL Neurotrophic regulation of two properties of skeletal muscle by impulse-dependent and spontaneous acetylcholine transmission. J Neurosci 1982; 2: 232-243
22. Lipsky NG, Drachman DB, Pestronk A, Shih P-J Neural regulation of mRNA for the α-subunit of acetylcholine receptors: role of neuromuscular transmission. Exp Neurol 1989; 105: 171-176
23. Asher O, Neumann D, Fuchs S Increased levels of acetylcholine receptor α-subunit mRNA in experimental autoimmune myasthenia gravis. FEBS Lett 1988; 233: 277-281
24. Cohen JB, Changeux J-P The cholinergic receptor protein in its membrane environment. Annu Rev Pharmacol 1975; 15: 83-103
25. Lindstrom J An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977; 7: 36-43
26. Noda M, Furutani Y, Takahashi H, Cloning and sequence analysis of calf cDNA and human genomic DNA encoding α-subunit precursor of muscle acetylcholine receptor. Nature 1983; 305: 818-823
27. Changeux J-P, Devillers-Thiery A, Chemouilli P Acetylcholine receptor: an allosteric protein. Science 1984; 225: 1335-1345
28. Beeson D, Brydson M, Wood H, Vincent A, Newsom-Davis J Human muscle acetylcholine receptor: cloning and expression in Escherichia coli of cDNA for the α-subunit. Biochem Soc Trans 1989; 17: 219-220
29. Talib S, Leiby KR, Wright K, Okarma TB Cloning and expression in Escherichia coli of a synthetic gene encoding the extracellular domain of the human muscle acetylcholine receptor α-subunit. Gene 1991; 98: 289-293
30. Witzemann V, Stein E, Barg B, Primary structure and functional expression of the α-, β-, γ-, δ-, and ε-subunits of the acetylcholine receptor from rat muscle. Eur J Biochem 1990; 194: 437-448
31. Drachman DB. How to recognize an antibody-mediated autoimmune disease: criteria. In: Waksman BH, ed. Immunologic mechanisms in neurologic and psychiatric disease. Vol. 68 of Research publications: Association for Research in Nervous and Mental Disease. New York: Raven Press, 1990:183-6.
32. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26: 1054-1059
33. Vincent A, Newsom-Davis J Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48: 1246-1252
34. Engel AG, Sahashi K, Lambert EH, Howard FM. The ultrastructural localization of the acetylcholine receptor, immunoglobulin G and the third and ninth complement components at the motor end-plate and their implications for the pathogenesis of myasthenia gravis. In: Aguayo AJ, Karpati G, eds. Current topics in nerve and muscle research. Amsterdam: Excerpta Medica, 1979:111-22.
35. Toyka KV, Drachman DB, Griffin DE, Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 1977; 296: 125-131
36. Lambert EH, Lindstrom JM, Lennon VA End-plate potentials in experimental autoimmune myasthenia gravis in rats. Ann N Y Acad Sci 1976; 274: 300-318
37. Penn AS, Chang HW, Lovelace RE, Niemi W, Miranda A Antibodies to acetylcholine receptors in rabbits: immunochemical and electrophysiological studies. Ann N Y Acad Sci 1976; 274: 354-376
38. Hertel G, Mertens HG, Reuther P, Ricker K. The treatment of myasthenia gravis with azathioprine. In: Dau PC, ed. Plasmapheresis and the immunobiology of myasthenia gravis. Boston: Houghton Mifflin, 1979:315-28.
39. Dau PC, Lindstrom JM, Cassel CK, Clark EC. Plasmapheresis in myasthenia gravis and polymyositis. In: Dau PC, ed. Plasmapheresis and the immunobiology of myasthenia gravis. Boston: Houghton Mifflin, 1979:229-47.
40. Kao I, Drachman DB Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 1977; 196: 527-529
41. Appel SH, Anwyl R, McAdams MW, Elias S Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins. Proc Natl Acad Sci U S A 1977; 74: 2130-2134
42. Drachman DB, Adams RN, Josifek LF, Self SG Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982; 307: 769-775
43. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 526-538
44. Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978; 298: 1116-1122
45. Pumplin DW, Drachman DB Myasthenic patients' IgG causes redistribution of acetylcholine receptors: freeze-fracture studies. J Neurosci 1983; 3: 576-584
46. Stanley EF, Drachman DB Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions. Science 1978; 200: 1285-1287
47. Engel AG, Arahata K The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 326-332
48. Vincent A, Whiting PJ, Schluep M, Antibody heterogeneity and specificity in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 106-120
49. Drachman DB, de Silva S, Ramsay D, Pestronk A Humoral pathogenesis of myasthenia gravis. Ann N Y Acad Sci 1987; 505: 90-105
50. Lindstrom J, Shelton D, Fujii Y Myasthenia gravis. Adv Immunol 1988; 42: 233-284
51. Tzartos SJ, Cung MT, Demange P, The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies. Mol Neurobiol 1991; 5: 1-29
52. Nielsen FC, Rodgaard A, Djurup R, Somnier F, Gammeltoft S A triple antibody assay for the quantitation of plasma IgG subclass antibodies to acetylcholine receptors in patients with myasthenia gravis. J Immunol Methods 1985; 83: 249-258
53. Mossman S, Vincent A, Newsom-Davis J Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet 1986; 1: 116-119
54. Soliven BC, Lange DJ, Penn AS, Seronegative myasthenia gravis. Neurology 1988; 38: 514-517
55. Drachman DB, DeSilva S, Ramsay D, Pestronk A “Sero-negative” myasthenia gravis: a humorally mediated variant of myasthenia. Neurology 1987; 37: Suppl 1: 214-214 abstract.
56. Brooks EB, Pachner AR, Drachman DB, Kantor FS A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: positive results in antibody negative' myasthenia gravis. J Neuroimmunol 1990; 28: 83-93
57. Yamamoto T, Vincent A, Ciulla TA, Lang B, Johnston I, Newsom-Davis J Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann Neurol 1991; 30: 550-557
58. Lennon VA, Lindstrom JM, Seybold ME Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci 1976; 274: 283-299
59. Abramsky O, Aharonov A, Webb C, Fuchs S Cellular immune response to acetylcholine receptor rich-fraction, in patients with myasthenia gravis. Clin Exp Immunol 1975; 19: 11-16
60. Richman DP, Antel JP, Patrick JW, Arnason BGW Cellular immunity to acetylcholine receptor in myasthenia gravis: relationship to histocompatibility type and antigenic site. Neurology 1979; 29: 291-296
61. Brocke S, Brautbar C, Steinman L, In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest 1988; 82: 1894-1900
62. Protti MP, Manfredi AA, Straub C, Wu XD, Howard JF Jr, Conti-Tronconi BM Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patients. J Immunol 1990; 144: 1711-1720
63. Newsom-Davis J, Harcourt G, Sommer N, Beeson D, Willcox N, Rothbard J-B T-cell reactivity in myasthenia gravis. J Autoimmun 1989; 2: Suppl: 101-108
64. Hohlfeld R, Toyka KV, Michels M, Heininger K, Conti-Tronconi B, Tzartos SJ Acetylcholine receptor-specific human T-lymphocyte lines. Ann N Y Acad Sci 1987; 505: 27-38
65. Link H, Olsson O, Sun J, Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest 1991; 87: 2191-2195
66. Yi Q, Pirskanen R, Lefvert AK Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis. J Neuroimmunol 1993; 42: 215-222
67. Melms A, Chrestel S, Schalke BC, Autoimmune T lymphocytes in myasthenia gravis: determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest 1989; 83: 785-790
68. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 1990; 28: 312-319
69. Sommer N, Harcourt GC, Willcox N, Beeson D, Newsom-Davis J Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 1991; 41: 1270-1276
70. Maselli RA, Richman DP, Wollmann RL Inflammation at the neuromuscular junction in myasthenia gravis. Neurology 1993; 41: 1497-1504
71. Nakano S, Murphy LM, Engel AG Cell-mediated versus humoral immune effector mechanisms in myasthenia gravis (MG). Neurology 1993; 43: Suppl: A181-A181 abstract.
72. Engel AG, Tsujihata M, Lambert EH, Lindstrom JM, Lennon VA Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations. J Neuropathol Exp Neurol 1976; 35: 569-587
73. Schwartz RH T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. Annu Rev Immunol 1985; 3: 237-261
74. Rudensky AY, Preston-Hurlburt P, Hong S-C, Barlow A, Janeway CA Jr Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353: 622-627
75. Melms A, Malcherek G, Gern U, T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the α-subunit. Ann Neurol 1992; 31: 311-318
76. Zhang Y, Schluep M, Frutiger S, Immunological heterogeneity of autoreactive T lymphocytes against the nicotinic acetylcholine receptor in myasthenic patients. Eur J Immunol 1990; 20: 2577-2583
77. Moiola L, Protti MP, Manfredi AA, Yuen MH, Howard JF Jr, Conti-Tronconi BM T-helper epitopes on human nicotinic acetylcholine receptor in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 198-218
78. Tesch H, Hohlfeld R, Toyka KV Analysis of immunoglobulin and T cell receptor gene rearrangements in the thymus of myasthenia gravis patients. J Neuroimmunol 1989; 21: 169-176
79. Grunewald J, Ahlberg R, Lefvert A-K, DerSimonian H, Wigzell H, Janson CH Abnormal T-cell expansion and V-gene usage in myasthenia gravis patients. Scand J Immunol 1991; 34: 161-168
80. Castleman B The pathology of the thymus gland in myasthenia gravis. Ann N Y Acad Sci 1966; 135: 496-505
81. Buckingham JM, Howard FM Jr, Bernatz PE, The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg 1976; 184: 453-458
82. Wekerle H, Paterson B, Ketelsen U-P, Feldman M Striated muscle fibres differentiate in monolayer cultures of adult thymus reticulum. Nature 1975; 256: 493-494
83. Kao I, Drachman DB Thymic muscle cells bear acetylcholine receptors: possible relation to myasthenia gravis. Science 1977; 195: 74-75
84. Wheatley LM, Urso D, Tumas K, Maltzman J, Loh E, Levinson AI Molecular evidence for the expression of nicotinic acetylcholine receptor α-chain in mouse thymus. J Immunol 1992; 148: 3105-3109
85. Kirchner T, Hoppe F, Schalke B, Muller-Hermelink HK Microenvironment of thymic myoid cells in myasthenia gravis. Virchows Arch [B] Cell Pathol 1988; 54: 295-302
86. Aoki T, Drachman DB, Asher DM, Gibbs CJ Jr, Bahmanyar S, Wolinsky JS Attempts to implicate viruses in myasthenia gravis. Neurology 1985; 35: 185-192
87. Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MBA Molecular mimicry and myasthenia gravis: an autoantigenic site of the acetylcholine receptor α-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989; 84: 1174-1180
88. Stefansson K, Dieperink ME, Richman DP, Gomez CM, Marton LS Sharing of antigenic determinants between the nicotinic acetylcholine receptor and proteins in Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae: possible role in the pathogenesis of myasthenia gravis. N Engl J Med 1985; 312: 221-225
89. Steinman L. Immunogenetic mechanisms in myasthenia gravis. In: Aquilonius S-M, Gillberg P-G, eds. Cholinergic neurotransmission: functional and clinical aspects. Vol. 84 of Progress in brain research. Amsterdam: Elsevier, 1990:117-24.
90. Carlsson B, Wallin J, Pirskanen R, Matell G, Smith CIE Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics 1990; 31: 285-290
91. Simpson JA Myasthenia gravis: a new hypothesis. Scott Med 1960; 5: 419-436
92. Oosterhuis HJGH. Clinical aspects. In: de Baets MH, Oosterhuis HJGH, eds. Myasthenia gravis. Boca Raton, Fla.: CRC Press, 1993:13-42.
93. Daroff RB The office Tensilon test for ocular myasthenia gravis. Arch Neurol 1986; 43: 843-844
94. Keesey JC Electrodiagnostic approach to defects of neuromuscular transmission. Muscle Nerve 1989; 12: 613-626
95. Stalberg E, Trontelj J. Single fibre electromyography. Old Woking, England: Mirvalle Press, 1979.
96. Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 1992; 15: 720-724
97. Penn AS, Richman DP, Ruff RL, Lennon VA, edsMyasthenia gravis and related disorders: experimental and clinical aspects. Ann N Y Acad Sci 1993; 681: 425-514
98. Bucknall RC, Dixon A St J, Glick EN, Woodland J, Zutshi DW Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. BMJ 1975; 1: 600-602
99. Kuncl RW, Pestronk A, Drachman DB, Rechthand E The pathophysiology of penicillamine-induced myasthenia gravis. Ann Neurol 1986; 20: 740-744
100. Howard JF Jr Adverse drug effects on neuromuscular transmission. Semin Neurol 1990; 10: 89-102
101. O'Neill JH, Murray NMF, Newsom-Davis J The Lambert-Eaton syndrome: a review of 50 cases. Brain 1988; 111: 557-596
102. Lang B, Johnston I, Leys K, Autoantibody specificities in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1993; 681: 382-393
103. Moraes CT, DiMauro S, Zeviani M, Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med 1989; 320: 1293-1299
104. Moorthy G, Behrens MM, Drachman DB, Ocular pseudomyasthenia or ocular myasthenia plus': a warning to clinicians. Neurology 1989; 39: 1150-1154
105. Batra P, Herrmann C Jr, Mulder D Mediastinal imaging in myasthenia gravis: correlation of chest radiography, CT, MR, and surgical findings. AJR Am J Roentgenol 1987; 148: 515-519
106. Grob D, Brunner NG, Namba T The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci 1981; 377: 652-669
107. Drachman DB. Myasthenia gravis. In: Johnson RT, Griffin JW, eds. Current therapy in neurologic disease. 4th ed. St. Louis: Mosby-Year Book, 1993:379-84.
108. Rowland LP General discussion on therapy in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 607-609
109. Seybold ME, Howard FM Jr, Duane DD, Payne WS, Harrison EG Jr Thymectomy in juvenile myasthenia gravis. Arch Neurol 1971; 25: 385-392
110. Olanow CW, Wechsler AS, Sirotkin-Roses M, Stajich J, Roses AD Thymectomy as primary therapy in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 595-606
111. Perlo VP, Arnason B, Castleman B The thymus gland in elderly patients with myasthenia gravis. Neurology 1975; 25: 294-295
112. Schumm F, Wietholter H, Fateh-Moghadam A, Dichgans J Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry 1985; 48: 332-337
113. Kuroda Y, Oda K, Neshige R, Shibasaki H Exacerbation of myasthenia gravis after removal of a thymoma having a membrane phenotype of suppressor T cells. Ann Neurol 1984; 15: 400-402
114. Younger DS, Jaretzki A III, Penn AS, Maximum thymectomy for myasthenia gravis. Ann N Y Acad Sci 1987; 505: 832-835
115. Cooper JD, Al-Jilaihawa AN, Pearson FG, Humphrey JG, Humphrey HE An improved technique to facilitate transcervical thymectomy for myasthenia gravis. Ann Thorac Surg 1988; 45: 242-247
116. Kirsch JR, Diringer MN, Borel CO, Hanley DF, Merritt WT, Bulkley GB Preoperative lumbar epidural morphine improves postoperative analgesia and ventilatory function after transsternal thymectomy in patients with myasthenia gravis. Crit Care Med 1991; 19: 1474-1479
117. Lindberg C, Andersen O, Larsson S, Oden A Remission rate after thymectomy in myasthenia gravis when the bias of immunosuppressive therapy is eliminated. Acta Neurol Scand 1992; 86: 323-328
118. Kuks JBM, Oosterhuis HJGH, Limburg PC, The TH Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis: clinical correlations. J Autoimmun 1991; 4: 197-211
119. Scadding GK, Vincent A, Newsom-Davis J, Henry K Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 1981; 31: 935-943
120. Johns TR Long-term corticosteroid treatment of myasthenia gravis. Ann N Y Acad Sci 1987; 505: 568-583
121. Seybold ME, Drachman DB Gradually increasing doses of prednisone in myasthenia gravis: reducing the hazards of treatment. N Engl J Med 1974; 290: 81-84
122. Handschumacher RE. Immunosuppressive agents. In: Gilman AG, Rall TW, Nies AS, Taylor P. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:1264-76.
123. Parrillo JE, Fauci AS Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol 1979; 19: 179-201
124. Tindall RS Humoral immunity in myasthenia gravis: effects of steroids and thymectomy. Neurology 1980; 30: 554-557
125. Abramsky O, Aharonov A, Teitelbaum D, Fuchs S Myasthenia gravis and acetylcholine receptor: effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch Neurol 1975; 32: 684-687
126. Kaplan I, Blakely BT, Pavlath GK, Travis M, Blau HM Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis. Proc Natl Acad Sci U S A 1990; 87: 8100-8104
127. Van Wilgenburg H The effect of prednisolone on neuromuscular transmission in the rat diaphragm. Eur J Pharmacol 1979; 55: 355-361
128. Galanaud P, Crevon MC, Erard D, Wallon C, Dormont J Two processes for B-cell triggering by T-independent antigens as evidenced by the effect of azathioprine. Cell Immunol 1976; 22: 83-92
129. Matell G Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann N Y Acad Sci 1987; 505: 588-594
130. Michels M, Hohlfeld R, Hartung H-P, Heininger K, Besinger UA, Toyka KV Myasthenia gravis: discontinuation of long-term azathioprine. Ann Neurol 1988; 24: 798-798
131. Kahan DB, Bach J-F, edsProceedings of the Second International Congress on Cyclosporine, November 4-7, 1987, Washington, D.C. II. Therapeutic use in transplantation. Transplant Proc 1988; 20: Suppl 3: 1-1131
132. Drachman DB, Adams RN, McIntosh K, Pestronk A Treatment of experimental myasthenia gravis with cyclosporin A. Clin Immunopathol 1985; 34: 174-188
133. Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 539-551
134. Flanagan WM, Corthesy F, Bram RJ, Crabtree GR Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 803-807
135. Schalke BCG, Kappos L, Rohrbach E, Ciclosporin A vs azathioprine in the treatment of myasthenia gravis: final results of a randomized, controlled double-blind clinical trial. Neurology 1988; 38: Suppl 1: 135-135 abstract.
136. Pinching AJ, Peters DK, Newsom-Davis J Remission of myasthenia gravis following plasma-exchange. Lancet 1976; 2: 1373-1376
137. Keesey J, Buffkin D, Kebo D, Ho W, Herrmann C Jr Plasma exchange alone as therapy for myasthenia gravis. Ann N Y Acad Sci 1981; 377: 729-743
138. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977; 297: 1134-1140
139. Evoli A, Bartoccioni E, Batocchi AP, Scuderi F, Tonali P Anti-AChR-negative myasthenia gravis: clinical and immunological features. Clin Invest Med 1989; 12: 104-109
140. Arsura E Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 1989; 53: Suppl: S170-S179
141. Dwyer JM Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-116
142. Drachman DB, McIntosh KR, Reim J, Balcer L Strategies for treatment of myasthenia gravis. Ann N Y Acad Sci 1993; 681: 515-528
143. Killen JA, Lindstrom JM Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates. J Immunol 1984; 133: 2549-2553
144. Sterz RK, Biro G, Rajki K, Filipp G, Peper K Experimental autoimmune myasthenia gravis: can pretreatment with 125I-labeled receptor prevent functional damage at the neuromuscular junction? J Immunol 1985; 134: 841-846
145. Berzofsky JA, Brett SJ, Streicher HZ, Takahashi H Antigen processing for presentation to T lymphoctyes: function, mechanisms, and implications for the T-cell repertoire. Immunol Rev 1988; 106: 5-31
146. Brostoff SW, Mason DW Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J Immunol 1984; 133: 1938-1942
147. Bach J-F Immunointervention in autoimmune diseases from cellular selectivity to autoantigen specificity. J Autoimmun 1992; 5: Suppl A: 3-10
148. Herzog C, Walker C, Muller W, Anti-CD4 antibody treatment of patients with rheumatoid arthritis. I. Effect on clinical course and circulating T cells. J Autoimmun 1989; 2: 627-642
149. Christadoss P, Dauphinee MJ Immunotherapy for myasthenia gravis: a murine model. J Immunol 1986; 136: 2437-2440
150. Ahlberg R, Yi Q, Pirskanen R, Clinical improvement of myasthenia gravis by treatment with a chimeric anti-CD4 monoclonal antibody. Ann N Y Acad Sci 1993; 681: 552-555
151. Waldmann TA The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986; 232: 727-732
152. Williams DP, Parker K, Bacha P, Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1987; 1: 493-498
153. Balcer LJ, McIntosh KR, Nichols JC, Drachman DB Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies. J Neuroimmunol 1991; 31: 115-122
154. Kiyokawa T, Williams DP, Snider CE, Strom TB, Murphy JR Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng 1991; 4: 463-468
155. Link H, Xu Z-Y, Melms A, The T-cell repertoire in myasthenia gravis involves multiple cholinergic receptor epitopes. Scand J Immunol 1992; 36: 405-414
156. Ashizawa T, Oshima M, Ruan K-H, Atassi MZ. Autoimmune recognition profile of the α chain of human acetylcholine receptor in myasthenia gravis. In: Atassi MZ, ed. Immunobiology of proteins and peptides VI: human immunodeficiency virus, antibody immunoconjugates, bacterial vaccines, and immunomodulators. Vol. 303 of Advances in experimental medicine and biology. New York: Plenum Press, 1991:255-61.
157. Reim J, McIntosh KR, Drachman D Acetylcholine receptor presentation by B cells using heterobifunctional antibody conjugates. Ann N Y Acad Sci 1993; 681: 325-328
158. Reim J, McIntosh KR, Martin S, Drachman DB Specific immunotherapeutic strategy for myasthenia gravis: targeted antigen-presenting cells. J Neuroimmunol 1992; 41: 61-70
159. Wells HG Studies on the chemistry of anaphylaxis (III): experiments with isolated proteins, especially those of the hen's egg. J Infect Dis 1911; 9: 147-171
160. Mowat AM The regulation of immune responses to dietary protein antigens. Immunol Today 1987; 8: 93-98
161. Thompson HS, Staines NA Could specific oral tolerance be a therapy for autoimmune disease? Immunol Today 1990; 11: 396-399
162. Weiner HL, Zhang ZJ, Khoury SJ, Antigen-driven peripheral immune tolerance: suppression of organ-specific autoimmune diseases by oral administration of autoantigens. Ann N Y Acad Sci 1991; 636: 227-232
163. Wang ZY, Qiao J, Link H Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993; 44: 209-214
164. Okumura S, McIntosh KM, Drachman DB. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol (in press).